Goldman Sachs’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-583
| Closed | -$36K | – | 5790 |
|
|
2020
Q3 | $36K | Sell |
583
-615
| -51% | -$46.4K | ﹤0.01% | 5216 |
|
|
2020
Q2 | $106K | Sell |
1,198
-1,850
| -61% | -$196K | ﹤0.01% | 4978 |
|
|
2020
Q1 | $341K | Buy |
3,048
+250
| +9% | +$49.2K | ﹤0.01% | 4428 |
|
|
2019
Q4 | $685K | Sell |
2,798
-304
| -10% | -$76.7K | ﹤0.01% | 4336 |
|
|
2019
Q3 | $1.07M | Sell |
3,102
-1,507
| -33% | -$819K | ﹤0.01% | 3983 |
|
|
2019
Q2 | $4.24M | Sell |
4,609
-1,062
| -19% | -$1.31M | ﹤0.01% | 2960 |
|
|
2019
Q1 | $9.04M | Sell |
5,671
-405
| -7% | -$730K | ﹤0.01% | 2500 |
|
|
2018
Q4 | $11.4M | Buy |
6,076
+449
| +8% | +$977K | ﹤0.01% | 2255 |
|
|
2018
Q3 | $13.3M | Sell |
5,627
-13
| -0.2% | -$40.2K | ﹤0.01% | 2236 |
|
|
2018
Q2 | $19.4M | Buy |
5,640
+1,313
| +30% | +$4.02M | 0.01% | 1894 |
|
|
2018
Q1 | $12.3M | Buy |
4,327
+450
| +12% | +$1.35M | ﹤0.01% | 2182 |
|
|
2017
Q4 | $9.98M | Sell |
3,877
-626
| -14% | -$1.78M | ﹤0.01% | 2455 |
|
|
2017
Q3 | $12.8M | Buy |
4,503
+45
| +1% | +$119K | ﹤0.01% | 2350 |
|
|
2017
Q2 | $10.5M | Buy |
4,458
+1,936
| +77% | +$3.84M | ﹤0.01% | 2483 |
|
|
2017
Q1 | $6.36M | Sell |
2,522
-348
| -12% | -$1M | ﹤0.01% | 2745 |
|
|
2016
Q4 | $6.47M | Sell |
2,870
-3,170
| -52% | -$7.54M | ﹤0.01% | 2827 |
|
|
2016
Q3 | $15.1M | Buy |
6,040
+3,601
| +148% | +$10.7M | ﹤0.01% | 2117 |
|
|
2016
Q2 | $7.46M | Buy |
2,439
+67
| +3% | +$218K | ﹤0.01% | 2553 |
|
|
2016
Q1 | $7.53M | Buy |
2,372
+588
| +33% | +$2.44M | ﹤0.01% | 2440 |
|
|
2015
Q4 | $9.16M | Buy |
1,784
+859
| +93% | +$3.75M | ﹤0.01% | 2320 |
|
|
2015
Q3 | $2.94M | Sell |
925
-1,538
| -62% | -$5.96M | ﹤0.01% | 3396 |
|
|
2015
Q2 | $9.85M | Buy |
2,463
+272
| +12% | +$1.05M | ﹤0.01% | 2347 |
|
|
2015
Q1 | $8.75M | Buy |
2,191
+637
| +41% | +$2.92M | ﹤0.01% | 2408 |
|
|
2014
Q4 | $7.62M | Sell |
1,554
-415
| -21% | -$1.78M | ﹤0.01% | 2590 |
|
|
2014
Q3 | $8M | Sell |
1,969
-476
| -19% | -$1.79M | ﹤0.01% | 2556 |
|
|
2014
Q2 | $9.89M | Sell |
2,445
-7,183
| -75% | -$29.3M | ﹤0.01% | 2375 |
|
|
2014
Q1 | $43.8M | Sell |
9,628
-2,816
| -23% | -$11.4M | 0.01% | 1151 |
|
|
2013
Q4 | $43.6M | Buy |
12,444
+4,290
| +53% | +$16.7M | 0.01% | 1152 |
|
|
2013
Q3 | $33.5M | Buy |
8,154
+2,158
| +36% | +$9.3M | 0.01% | 1245 |
|
|
2013
Q2 | $23.7M | Buy |
+5,996
| New | +$24.7M | 0.01% | 1408 |
|
Other funds holding ACOR
BCM
Goldman Sachs's ACOR Position: Q4 2020 in Review
Goldman Sachs sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 583 shares — an estimated $36K sold.
Goldman Sachs first reported a position in ACOR in Q2 2013 and held it in 30 quarters. The position peaked at $43.8M in Q1 2014. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.
- Goldman Sachs reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
- Goldman Sachs sold 583 Acorda Therapeutics shares in Q4 2020, an estimated $36K.
- Goldman Sachs first reported a position in Acorda Therapeutics in Q2 2013 and held it in 30 quarters.
- Goldman Sachs's Acorda Therapeutics position peaked at $43.8M in Q1 2014.
- 47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.